Trevi Therapeutics

$2.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.02 (+0.85%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell TRVI and other stocks, options, and ETFs commission-free!

About TRVI

Trevi Therapeutics, Inc. Common Stock, also called Trevi Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT. The listed name for TRVI is Trevi Therapeutics, Inc. Common Stock.

CEO
Jennifer L. Good
Employees
17
Headquarters
New Haven, Connecticut
Founded
2011
Market Cap
50.42M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
103.05K
High Today
$2.42
Low Today
$2.13
Open Price
$2.36
Volume
113.80K
52 Week High
$8.50
52 Week Low
$1.33

TRVI Earnings

-$0.48
-$0.32
-$0.16
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
—

You May Also Like

BMTX+
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure